NCT00973739 - Lapatinib Study for Children and Adults With Neurofibromatosis Type 2 (NF2) and NF2-Related Tumors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 30, 2009

Primary Completion Date

October 31, 2012

Study Completion Date

November 30, 2012

Conditions

Neurofibromatosis 2Vestibular Schwannoma

Interventions

DRUG

Lapatinib

"Lapatinib is dosed according to age. Lapatinib is available in 250 mg tablets only. For pediatric dosing, the total daily dose will be rounded up or down to the nearest 250 mg increment.~Children/adolescents (\<18 years of age): 1,800 mg/m2/day PO divided into twice daily doses, to a maximum of 750 mg PO (3 tablets twice daily)~Adults (\>=18 years of age): 1,500 mg PO (6 tablets once daily)~Duration: Up to 12 months, depending on treatment response."

Trial Locations (1)

10016

New York University School of Medicine, New York